Cargando…

New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review

Pulmonary alveolar microlithiasis (PAM) is a rare autosomal recessive lung disease caused by variants in the SLC34A2 gene encoding the sodium-dependent phosphate transport protein 2B, NaPi-2b. PAM is characterized by deposition of calcium phosphate crystals in the alveoli. Onset and clinical course...

Descripción completa

Detalles Bibliográficos
Autores principales: Jönsson, Åsa Lina M., Hilberg, Ole, Simonsen, Ulf, Christensen, Jane Hvarregaard, Bendstrup, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230741/
https://www.ncbi.nlm.nih.gov/pubmed/37259144
http://dx.doi.org/10.1186/s13023-023-02712-7
_version_ 1785051600787603456
author Jönsson, Åsa Lina M.
Hilberg, Ole
Simonsen, Ulf
Christensen, Jane Hvarregaard
Bendstrup, Elisabeth
author_facet Jönsson, Åsa Lina M.
Hilberg, Ole
Simonsen, Ulf
Christensen, Jane Hvarregaard
Bendstrup, Elisabeth
author_sort Jönsson, Åsa Lina M.
collection PubMed
description Pulmonary alveolar microlithiasis (PAM) is a rare autosomal recessive lung disease caused by variants in the SLC34A2 gene encoding the sodium-dependent phosphate transport protein 2B, NaPi-2b. PAM is characterized by deposition of calcium phosphate crystals in the alveoli. Onset and clinical course vary considerably; some patients remain asymptomatic while others develop severe respiratory failure with a significant symptom burden and compromised survival. It is likely that PAM is under-reported due to lack of recognition, misdiagnosis, and mild clinical presentation. Most patients are genetically uncharacterized as the diagnostic confirmation of PAM has traditionally not included a genetic analysis. Genetic testing may in the future be the preferred tool for diagnostics instead of invasive methods. This systematic review aims to provide an overview of the growing knowledge of PAM genetics. Rare variants in SLC34A2 are found in almost all genetically tested patients. So far, 34 allelic variants have been identified in at least 68 patients. A majority of these are present in the homozygous state; however, a few are found in the compound heterozygous form. Most of the allelic variants involve only a single nucleotide. Half of the variants are either nonsense or frameshifts, resulting in premature termination of the protein or decay of the mRNA. There is currently no cure for PAM, and the only effective treatment is lung transplantation. Management is mainly symptomatic, but an improved understanding of the underlying pathophysiology will hopefully result in development of targeted treatment options. More standardized data on PAM patients, including a genetic diagnosis covering larger international populations, would support the design and implementation of clinical studies to the benefit of patients. Further genetic characterization and understanding of how the molecular changes influence disease phenotype will hopefully allow earlier diagnosis and treatment of the disease in the future.
format Online
Article
Text
id pubmed-10230741
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102307412023-06-01 New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review Jönsson, Åsa Lina M. Hilberg, Ole Simonsen, Ulf Christensen, Jane Hvarregaard Bendstrup, Elisabeth Orphanet J Rare Dis Review Pulmonary alveolar microlithiasis (PAM) is a rare autosomal recessive lung disease caused by variants in the SLC34A2 gene encoding the sodium-dependent phosphate transport protein 2B, NaPi-2b. PAM is characterized by deposition of calcium phosphate crystals in the alveoli. Onset and clinical course vary considerably; some patients remain asymptomatic while others develop severe respiratory failure with a significant symptom burden and compromised survival. It is likely that PAM is under-reported due to lack of recognition, misdiagnosis, and mild clinical presentation. Most patients are genetically uncharacterized as the diagnostic confirmation of PAM has traditionally not included a genetic analysis. Genetic testing may in the future be the preferred tool for diagnostics instead of invasive methods. This systematic review aims to provide an overview of the growing knowledge of PAM genetics. Rare variants in SLC34A2 are found in almost all genetically tested patients. So far, 34 allelic variants have been identified in at least 68 patients. A majority of these are present in the homozygous state; however, a few are found in the compound heterozygous form. Most of the allelic variants involve only a single nucleotide. Half of the variants are either nonsense or frameshifts, resulting in premature termination of the protein or decay of the mRNA. There is currently no cure for PAM, and the only effective treatment is lung transplantation. Management is mainly symptomatic, but an improved understanding of the underlying pathophysiology will hopefully result in development of targeted treatment options. More standardized data on PAM patients, including a genetic diagnosis covering larger international populations, would support the design and implementation of clinical studies to the benefit of patients. Further genetic characterization and understanding of how the molecular changes influence disease phenotype will hopefully allow earlier diagnosis and treatment of the disease in the future. BioMed Central 2023-05-31 /pmc/articles/PMC10230741/ /pubmed/37259144 http://dx.doi.org/10.1186/s13023-023-02712-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Jönsson, Åsa Lina M.
Hilberg, Ole
Simonsen, Ulf
Christensen, Jane Hvarregaard
Bendstrup, Elisabeth
New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review
title New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review
title_full New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review
title_fullStr New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review
title_full_unstemmed New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review
title_short New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review
title_sort new insights in the genetic variant spectrum of slc34a2 in pulmonary alveolar microlithiasis; a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230741/
https://www.ncbi.nlm.nih.gov/pubmed/37259144
http://dx.doi.org/10.1186/s13023-023-02712-7
work_keys_str_mv AT jonssonasalinam newinsightsinthegeneticvariantspectrumofslc34a2inpulmonaryalveolarmicrolithiasisasystematicreview
AT hilbergole newinsightsinthegeneticvariantspectrumofslc34a2inpulmonaryalveolarmicrolithiasisasystematicreview
AT simonsenulf newinsightsinthegeneticvariantspectrumofslc34a2inpulmonaryalveolarmicrolithiasisasystematicreview
AT christensenjanehvarregaard newinsightsinthegeneticvariantspectrumofslc34a2inpulmonaryalveolarmicrolithiasisasystematicreview
AT bendstrupelisabeth newinsightsinthegeneticvariantspectrumofslc34a2inpulmonaryalveolarmicrolithiasisasystematicreview